Japan

Some good news for men who are living in Japan and dealing with advanced prostate cancer. It was announced that Astellas and Medivation have submitted an application for marketing approval of Enzalutamide (Xtandi) in Japan. Their application is based on results obtained from the global Phase 3 trial (the AFFIRM trial)* and a Phase 1-2 [...]